CG
ATXS

Cutler Group’s Astria Therapeutics ATXS Stock Holding History

Cutler Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2K Buy
+4,900
New +$61K ﹤0.01% 1798

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's ATXS Position: Q4 2021 in Review

Cutler Group sold out of Astria Therapeutics (ATXS) in Q4 2021, closing a stake of 116 shares — an estimated $1K sold.

Cutler Group first reported a position in ATXS in Q4 2020 and held it in 4 quarters. The position peaked at $3K in Q4 2020. 33 funds tracked by Wall St. Rank hold ATXS as of Q4 2021.

  • Cutler Group reported no remaining Astria Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 116 Astria Therapeutics shares in Q4 2021, an estimated $1K.
  • Cutler Group first reported a position in Astria Therapeutics in Q4 2020 and held it in 4 quarters.
  • Cutler Group's Astria Therapeutics position peaked at $3K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.